Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers

Journal of Emergency Medicine

Volumn 26, Issue 3, 2004, Pages 309-314

  Love, Jeffrey N ^a,c   Sikka, Neal ^b   Klein Schwartz, Wendy ^d   Curtis, Liesl ^c  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d Maryland Poison Center   (United States)

Author keywords

Beta blockers; Overdose; Pediatrics; Toxicity

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BISOPROLOL FUMARATE; CHARCOAL; DORZOLAMIDE PLUS TIMOLOL; HYDROCHLOROTHIAZIDE; HYPERTENSIVE FACTOR; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NADOLOL; PHOSPHODIESTERASE INHIBITOR; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; TIMOLOL MALEATE;

CARDIOTOXICITY; CAUSE OF DEATH; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG INTOXICATION; DRUG OVERDOSE; FIRST PASS EFFECT; HUMAN; HYDROPHILICITY; HYPOTENSION; INGESTION; LIPOPHILICITY; LONG TERM CARE; MORBIDITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 1542613780     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2003.11.015     Document Type: Article

References (38)

1. Artman M., Grayson M., Boerth R.C. Propranolol in children safety-toxicology. Pediatrics. 70:1982;30-32.
2. Brubacher J.R. Beta-adrenergic antagonists. Goldfrank L.R., Flomenbaum N.E., Lewin N.A., Howland M.A., Hoffman R.S., Nelson L.S. Goldfrank's toxicologic emergencies. 7th edn. 2002;741-757 McGraw-Hill, New York.
3. Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J. 97:1979;663-670.
4. Matthews J.C., Baker J.K. Effects of propranolol and a number of its analogues on sodium channels. Biochem Pharmacol. 31:1982;1681-1685.
5. Love J.N., Elshami J. Cardiovascular depression resulting from atenolol intoxication. Eur J Emerg Med. 9:2002;111-114.
6. Frishman W., Jacob H., Eisenberg E., Ribner H. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents recognition and management. Am Heart J. 98:1979;798-811.
7. Love J.N., Leasure J.A., Mundt D.J., Janz T.G. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol. 30:1992;399-412.
8. Love J.N., Enlow B., Howell J.M., Klein-Schwartz W., Litovitz T.L. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med. 40:2002;603-610.
9. Neuvonen P.J., Elonen E., Vuorenmaa T., Laakso M. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. Eur J Clin Pharmacol. 20:1981;85-89.
10. Love J.N. Beta-blocker toxicity after overdose when do symptoms develop in adults? J Emerg Med. 12:1994;799-802.
11. Patterson J.W., Conolly M.E., Dollery C.T., Hayes A., Cooper R.G. The pharmacodynamics and metabolism of propranolol in man. Pharmacologia Clinica. 2:1970;127.
12. Flouvat B., Roux A., Chau N.P., et al. Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. Eur J Clin Pharmacol. 19:1981;287-292.
13. Frishman W., Silverman R. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects. Am Heart J. 97:1979;797-807.
14. Deacon S.P., Karunanayake A., Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J. 2:1977;1255-1257.
15. Kallen R.J., Mohler J.H., Lin H.L. Hypoglycemia a complication of treatment of hypertension with propranolol. Clin Pediatr (Phila). 19:1980;567-568.
16. Love J.N., Handler J.A. Toxic psychosis an unusual presentation of propranolol intoxication. Am J Emerg Med. 13:1995;536-537.
17. Soni N., Baines D., Pearson I.Y. Cardiovascular collapse and propranolol overdose. Med J Aust. 2:1983;629-630.
18. Chyka P.A., Seger D. Position statement single-dose activated charcoal. American Academy of Clinical Toxicology; European Associations of Poisons Centres and Clinical Toxicologist. J Toxicol Clin Toxicol. 35:1997;721-741.
19. Green R., Grierson R., Sitar D.S., Tenenbein M. How long after drug ingestion is activated charcoal still effective? J Toxicol Clin Toxicol. 39:2001;601-605.
20. Reith D.M., Dawson A.H., Epid D., Whyte I.M., Buckley N.A., Sayer G.P. Relative toxicity of beta-blockers in overdose. J Toxicol Clin Toxicol. 34:1996;273-278.
21. Veltri J.C., Litovitz T.L. 1983 Annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 2:1984;443-535.
22. Litovitz T.L., Klein-Schwartz W., Rodgers G.C. Jr, et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 20:2002;391-452.
23. Litovitz T.L., Veltri J.C. 1984 Annual report of the American Association Of Poison Control Centers National Data Collection System. Am J Emerg Med. 3:1985;423-450.
24. Love J.N., Litovitz T.L., Howell J.M., Clancy C. Characterization of fatal beta-blocker ingestion a review of the American Association of Poison Control Centers data from 1985 to 1995. J Toxicol Clin Toxicol. 35:1997;353-359.
25. Litovitz T.L., Smilkstein M., Felberg L., Klein-Schwartz W., Berlin R., Morgan J.L. 1996 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 15:1997;447-500.
26. Litovitz T.L., Klein-Schwartz W., Dyer K.S., Shannon M., Lee S., Powers M. 1997 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 16:1998;443-497.
27. Litovitz T.L., Klein-Schwartz W., Caravati E.M., Youniss J., Crouch B., Lee S. 1998 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 17:1999;435-487.
28. Litovitz T.L., Klein-Schwartz W., White S., et al. 1999 Annual report of the American Association Of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 18:2000;517-574.
29. Litovitz T.L., Klein-Schwartz W., White S., et al. 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 19:2001;337-395.
30. Litovitz T.L., Schmitz B.F., Matyunas N., Martin T.G. 1987 Annual report of the American Association Of Poison Control Centers National Data Collection System. Am J Emerg Med. 6:1988;479-515.
31. Belson M.G., Sullivan K., Geller R.J. Beta-adrenergic antagonist exposures in children. Vet Hum Toxicol. 43:2001;361-365.
32. Gillette P., Garson A. Jr, Eterovic E., Neches W., Mullins C., McNamara D.G. Oral propranolol treatment in infants and children. J Pediatr. 92:1978;141-144.
33. Hesse B., Pedersen J.T. Hypoglycaemia after propranolol in children. Acta Med Scand. 193:1973;551-552.
34. McBride J.T., McBride M.C., Viles P.H. Hypoglycemia associated with propranolol. Pediatrics. 51:1973;1085-1087.
35. Zeligs M.A., Lockhart C.H. Perioperative hypoglycemia in a child treated with propranolol. Anesth Analg. 62:1983;1035-1037.
36. Feller J.M. Danger of hypoglycaemia with use of propranolol. Med J Aust. 2:1973;92.
37. Pfammatter J.P., Paul T. New antiarrhythmic drug in pediatric use sotalol. Pediatr Cardiol. 18:1997;28-34.
38. Celiker A., Ayabakan C., Ozer S., Ozme S. Sotalol in treatment of pediatric cardiac arrhythmias. Pediatr Int. 43:2001;624-630.